Roche agrees to buy Promedior for up to $1.4bn
Roche has signed a definitive merger agreement to acquire US-based biotechnology firm Promedior...
Focus:
-
![Sarepta and StrideBio sign gene therapy development deal]()
Sarepta and StrideBio sign gene therapy development deal
-
![Bayer invests $100m for alliance with Dewpoint Therapeutics]()
Bayer to invest $100m for alliance with Dewpoint Therapeutics
-
![Merck acquires Calporta Therapeutics for $576m]()
Merck acquires Calporta Therapeutics for $576m
-
![Novartis’ Sandoz to acquire Aspen Japan]()
Novartis’ Sandoz to acquire Aspen Japan for $331m
-
![Regeneron and Vyriad to develop oncolytic virus therapies]()
Regeneron and Vyriad to develop oncolytic virus therapies
-
![Biogen signs commercialisation deal with Samsung Bioepis]()
Biogen signs commercialisation deal with Samsung Bioepis
Most Read
- UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
- Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250m
- Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
- Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
- Boehringer acquires AMAL Therapeutics for $366m
Latest Content
Roche agrees to buy Promedior for up to $1.4bn
Roche has signed a definitive merger agreement to acquire US-based biotechnology firm Promedior for a total consideration of up to $1.4bn.
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
Bayer to invest $100m for alliance with Dewpoint Therapeutics
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
Merck acquires Calporta Therapeutics for $576m
Merck (MSD) has acquired small molecule therapies developer Calporta Therapeutics for a total consideration of approximately $576m.
Skyhawk and Celgene expand alliance to identify new drug targets
Skyhawk Therapeutics has formed a second alliance with an affiliate of Celgene to identify drug targets in autoimmune diseases, oncology and immuno-oncology.
Vaximm partners with NEC on neoantigen cancer vaccines
Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines.
Lupin to divest Kyowa Pharmaceutical for $526m
Pharmaceutical company Lupin has agreed to divest its stake in Kyowa Pharmaceutical Industry to private equity firm Unison Capital Partners’ entity Plutus for JPY57.4bn ($526m).
Novartis’ Sandoz to acquire Aspen Japan for $331m
Novartis subsidiary Sandoz has signed an agreement to buy Aspen Japan operations and related intellectual property from Aspen Global for an upfront payment of €300m ($331m) in cash.
Newpharma collaborates with Ingenico for e-payments
Belgian online pharmacy firm Newpharma has partnered with UK-based payments company Ingenico Group to enable secure payments for pharmaceutical buyers.
Regeneron and Vyriad to develop oncolytic virus therapies
Regeneron Pharmaceuticals has formed a five-year alliance with Vyriad for the development of oncolytic virus-based treatments for cancer.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
